ReviewCurrent opinion in immunology2017
No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.
Review in Current opinion in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety of the Sputnik V Vaccine in Health Personnel of Private Effectors of the City of Buenos Aires, Argentina
Immunity Against the COVID-19 Vaccine in Healthcare Workers of Buenos Aires, Argentine.
Safety and Efficacy of the Coronavirus Disease 2019 Vaccine in Hemodialysis Patients
Who cites it
40 citing papers in PubMed, 70 citations in OpenAlex.
- Biodegradable Polymers for Application as Robust Immunomodulatory Biomaterial Carrier Systems.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Innovative adjuvant strategies for next-generation pertussis vaccines.Human vaccines & immunotherapeutics · 2025Review
- Article
- Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded.Infectious agents and cancer · 2025Review
- Evaluating the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults: a systematic review and meta-analysis of randomized controlled trials.Therapeutic advances in vaccines and immunotherapy · 2025Review
- Molecular ingredients of an immunogen for long-lasting IgG.Frontiers in immunology · 2025Review
- Harnessing immunotherapeutic molecules and diagnostic biomarkers as human-derived adjuvants for MERS-CoV vaccine development.Frontiers in immunology · 2025Review
- Article
- Adjuvants for cancer mRNA vaccines in the era of nanotechnology: strategies, applications, and future directions.Journal of nanobiotechnology · 2024Review
- BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models.Infection and immunity · 2024Article
- Alcaligenes lipid A functions as a superior mucosal adjuvant to monophosphoryl lipid A via the recruitment and activation of CD11b+ dendritic cells in nasal tissue.International immunology · 2024Article
- Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen.NPJ vaccines · 2023Article
- Review
- Photoacoustic Imaging of COVID-19 Vaccine Site Inflammation of Autoimmune Disease Patients.Sensors (Basel, Switzerland) · 2023Article
- Article
- Side Effects Associated With Homologous and Heterologous COVID-19 Vaccines: A Cross-Sectional Study in Saudi Arabia.Cureus · 2023Article
- Article
- Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.Immunology letters · 2022Article
- Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis.Vaccines · 2022Article
- Governing HPV-related carcinoma using vaccines: Bottlenecks and breakthroughs.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Development of non-infectious subunit vaccines is hampered by a slow pipeline of new adjuvants to replace or enhance alum in part because expectations of safety are high. Transient vaccine side effects are not clinical priorities because they cause no lasting harm and vaccine development has appropriately been focused on avoidance of serious adverse events. As a result, surprisingly little is known about the extent to which side effects caused by a vaccine's reactogencicity are predictive of successful immunization outcomes. Recent clinical studies of pertussis and human papillomavirus vaccines adjuvanted with alum or the TLR4 agonist monophosphoryl lipid A can be used to advance understanding of the relationship between vaccine side effects and immunization outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.